Ja, Celgene mente at de så liten effekt som monoterapi og la derfor ned den studien, men fortsetter er kombinasjonsstudie de også kjører på CD47. Resultatene som kom frem nå er fra et studie med selskapet FortySeven sitt anit-CD47 mAb. FortySeven kjører også et monoterapistudie, men jeg har ikke sett noen resultater derfra enda. Vanligvis så vil null effekt som monoterapi få alarmbjellene til å ringe, men dette var pasienter som var heavily pre-treated R/R og 90% var rituximab-refractory. Det virker også logiskt at denne mekanismen kan ha en effekt som kombinasjonsbehandling uten å ha noe effekt som monoterapi.
Så denne behandlingen kan da også passe bra i en kombinasjon med RIT+Rituximab da muligens.
Finner du at de er heavily pretreated? Jeg finner bare at de er rituximab refractory, og det kan jo også være at de fikk relapse <6Mnd etter front line treatment. Jeg mener vi trenger mer info for å si noe særlig, egentlig.
Det vet vi jo ikke, men ja, jeg vil tro det er mulig. Tanken her er at CD47 fungere som en immunhemmer av macrophager, immunceller som spiser opp syke, gamle og skadet celler. Hvis du da fjerner denne hemmningen så vil muligens det meste av mAb som fungerer ved ADCC og CDC fungere bedre? Tror det er noe sånn de sikter seg inn på.
@Fornybar Det står i ASCO abstractet: https://meetinglibrary.asco.org/record/159490/abstract
Background: Targeted non-cytotoxic therapies are needed in relapsed/refractory (r/r) NHL. Hu5F9-G4 (5F9) is a first-in-class humanized antibody targeting CD47, a protective “don’t eat me” signal on cancers, that stimulates tumor cell phagocytosis and an anti-tumor T cell response. Pre-clinically, 5F9 synergizes with rituximab to eliminate lymphoma by enhancing Fc receptor-mediated antibody-dependent cellular phagocytosis. This trial is the first to explore clinical activity of an anti-CD47 antibody+rituximab. Methods: This Phase 1b/2 enrolled r/r NHL patients in a 3+3 dose escalation design (NCT02953509). A 1 mg/kg 5F9 priming dose with higher weekly maintenance doses was used to mitigate on-target toxicities, specifically anemia. Maintenance doses were escalated from 10 to 30 mg/kg with standard dose rituximab. Results: 22 heavily pre-treated patients with r/r DLBCL (n = 15) and FL (n = 7) were enrolled in Phase 1b. Patients had a median of 4 prior therapies (range 2-9), 90% were rituximab-refractory. 5F9+rituximab was well-tolerated. Common treatment-related AEs were chills (41%), headache (36%), anemia (32%), and fever (27%). All were grade 1-2 except 3 G3 AEs (chills, fever, anemia). Prime/maintenance 5F9 dosing significantly mitigated on-target anemia, a mostly first dose effect with spontaneous recovery. Only 2 patients required a one-time transfusion. The MTD was not reached up to 30 mg/kg weekly of 5F9 dosing. > 90% CD47 receptor occupancy was achieved on peripheral blood cells, showing high target saturation. A Phase 2 dose of 30 mg/kg 5F9 Q2 weeks after cycle 1 was selected. Across all doses, the ORR was 50%, 32% achieved CR. %ORR/CR was 40/27 in DLBCL and 71/43 in FL, respectively. As of 1/16/2018, 90% of responding patients continued in response (4.4 month median follow up), including 1 patient for 13+ months. Conclusions: 5F9 + rituximab is a novel immunotherapy that inhibits a key macrophage/cancer checkpoint. It is well tolerated with no MTD reached and has promising clinical activity in rituximab-refractory DLBCL and FL patients including multiple CRs. Phase 2 cohorts are ongoing in indolent lymphoma and DLBCL Clinical trial information: NCT02953509
2 Likes
Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre 
Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.
Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:
- @Fornybar (1157 likes)
- @Savepig (702 likes)
- @studenten86 (621 likes)
Resten av topp 10:
-
@anon21766851 (604 likes)
-
@Nocturne (441 likes)
-
@Inkognito666 (404 likes)
-
@Oilimp (263 likes)
-
@vegar_beider (227 likes)
-
@Hallakis (223 likes)
-
@Mr.Oncoinvest (208 likes)
Gratulerer!
6 Likes
paging dr @larsmkn - hvordan i alle dager tolker man disse Best percent change -plottene?
Hvorfor er det framstilt som CR og PR når %-change from baseline er langt under 100%?
Never mind, fant en del info her
1 Like
Er dette plottet til CD47 behandlingen?
Ja. Hentet fra seneste investorpresentasjonen på nettsiden.
Kommer det en melding om 25 min, eller meldes abstraktene like før ASH presentasjonene skal holdes i desember?
24 minutes my friend…
Jeg er ihvertfall på riktig side av døgnet denne gangen
Nordic Nanovector highlights promising clinical results from Phase 1/2 trial of Betalutin® in relapsed/refractory indolent non-Hodgkin’s lymphoma
· Overall response rates of 69% in Arm 4 (100 mg/m2 lilotomab followed by 20 MBq/kg Betalutin®) and 64% in Arm 1 (40 mg lilotomab followed by 15 MBq/kg Betalutin®) in relapsed/refractory follicular lymphoma patients
· Median duration of response of 13.3 months for all patients (20.5 months for those with a complete response)
· Well tolerated with predictable and manageable safety profileNordic Nanovector ASA (OSE: NANO) announces that an abstract reporting updated results from its LYMRIT 37-01 Phase 1/2 clinical study of Betalutin® (177Lu-satetraxetan-lilotomab) in patients with relapsed/refractory indolent non-Hodgkin’s lymphoma (iNHL) has been published ahead of its presentation in a poster at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition (1-4 December 2018 in San Diego, CA, USA).
The published dataset (as of 22 June 2018) includes 74 evaluable patients; all patients received Betalutin® as a single administration and have six or more months of follow-up. The complete dataset will be presented at ASH.
The conclusions from the updated study results are that Betalutin® is well-tolerated and has promising anti-tumour activity in recurrent iNHL, especially in follicular lymphoma (FL) patients. Key results are:
±--------------------------±--------±------------±----------------------+
Patients Number of Overall Complete Responses (CR)
patients Response Rate
(n) (ORR)
±--------------------------±--------±------------±----------------------+
All iNHL patients 74 61 % 26 %
±--------------------------±--------±------------±----------------------+
FL patients 57 65 % 24 %
±--------------------------±--------±------------±----------------------+
3L FL patients (≥2 prior 37 70 % 27 %
therapies)
±--------------------------±--------±------------±----------------------+
FL patients in Arm 1 25 64 % 28 %
(40 mg lilotomab followed
by 15 MBq/kg Betalutin®)
±--------------------------±--------±------------±----------------------+
FL patients in Arm 4 16 69 % 19 %
(100 mg/m2 lilotomab
followed by 20 MBq/kg
Betalutin®)
±--------------------------±--------±------------±----------------------+The median duration of response (mDoR), when treated with a single administration of Betalutin®, was 13.3 months for all patients (20.5 months for those with a CR) based on a median follow-up of 9.1 months (range 4.9-49.5 months). Twenty-six patients (35%) have remained free of disease progression for more than 12 months.
Betalutin® therapy was well tolerated with no unexpected safety findings and the safety profile is both predictable and manageable.
The data continue to highlight the encouraging clinical profile of single-agent Betalutin® therapy in iNHL patients, particularly in those with FL, the primary NHL population for which Betalutin® is being developed.
Two recommended Phase 2 doses were identified from this study and are now being compared in the pivotal, randomised Phase 2b PARADIGME trial in relapsed, anti-CD20 refractory FL patients who have received two or more prior therapies.
Arne Kolstad, lead investigator of LYMRIT 37-01 and senior consultant in medical oncology and radiotherapy, Oslo University Hospital Radiumhospitalet, said: “Patients with relapsed/refractory follicular lymphoma have a need for effective treatment options that improve their quality of life, especially elderly patients. The clinical profile that Betalutin® is consistently showing in this patient population is very encouraging.”
Lisa Rojkjaer, Chief Medical Officer of Nordic Nanovector, commented: “We are very pleased with the clinical data. The results from Arm 4 further support the decision to compare the 100 mg/m2 lilotomab + 20 MBq/kg Betalutin® dosing regimen from Arm 4 with the 40 mg lilotomab + 15 MBq/kg regimen from Arm 1 in the pivotal phase 2b PARADIGME trial. The emerging data on the durability of the responses together with the safety profile of Betalutin® and the convenience of a single administration underscore the potential of Betalutin® for the treatment of patients with advanced-stage follicular lymphoma.”
Poster details
Abstract 2879
Abstract title: LYMRIT 37-01: A phase I/II study of 177Lu-lilotomab satetraxetan (Betalutin®) antibody-radionuclide-conjugate (ARC) for the treatment of relapsed non-Hodgkin’s lymphoma (NHL) - Analysis with 6-month follow-up
Authors: A. Kolstad, A et al.
Session Name: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma-Clinical Studies: Poster II
Date: Sunday, 2 December 2018
Presentation Time: 6:00 PM - 8:00 PM Pacific time
Location: San Diego Convention Center, Hall GH
The abstract is available at http://www.hematology.org/Annual-Meeting/ and the poster will be published on the Nordic Nanovector website to coincide with the session.
About ASH
The ASH annual meeting is the premier event for scientific exchange in the field of haematology, attracting more than 20,000 attendees from all over the world. Typically, more than 5,000 scientific abstracts are submitted each year, and more than 3,000 abstracts are accepted for oral and poster presentations through an extensive peer review process.
About LYMRIT 37-01
LYMRIT 37-01 is a Phase 1/2 dose-escalation study to determine the safety, pharmacokinetics and preliminary efficacy of a single dose of Betalutin® in patients with relapsed iNHL, and to establish a recommended Phase 2 dose for the global, randomised Phase 2b PARADIGME trial.
LYMRIT 37-01 recruited 74 pts [57 follicular (FL), 7 mantle cell (MCL), 9 marginal zone (MZL), 1 small lymphocytic (SLL)] at 13 sites between December 2012 and February 2018. Median age was 68 years (range 38-87; 55% ≥ 65); the median number of prior therapies was 3 (range 1-9); 48 pts (65%) received 2 or more prior therapies.
For further information, please contact:
IR enquiries
Malene Brondberg, VP Investor Relations and Corporate Communications
Cell: +44 7561 431 762
Email: [email protected]
International Media Enquiries
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44 207 638 9571
Email: [email protected]
About Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information can be found at www.nordicnanovector.com
Forward-looking statements
This press release contains certain forward-looking statements. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector’s business, financial condition and results of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”, “estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”, “should”, “projects”, “targets”, “will”, “would” or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. These forward-looking statements are not historic facts. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in the forward-looking statements. Factors that could cause these differences include, but are not limited to, risks associated with implementation of Nordic Nanovector’s strategy, risks and uncertainties associated with the development and/or approval of Nordic Nanovector’s product candidates, ongoing and future clinical trials and expected trial results, the ability to commercialise Betalutin®, technology changes and new products in Nordic Nanovector’s potential market and industry, Nordic Nanovector’s freedom to operate (competitors patents) in respect of the products it develops, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions, and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This information is subject to a duty of disclosure pursuant to Section 5-12 of the Securities Trading Act.
Nyheten er levert av Cision.
http://www.netfonds.no/quotes/release.php?id=20181101.Cision.20181101:BIT:8969:0
3 Likes
Nordic Nanovector highlights promising clinical results from Phase 1/2 trial of Betalutin® in relapsed/refractory indolent non-Hodgkin’s lymphom
. Overall response rates of 69% in Arm 4 (100 mg/m2 lilotomab followed by 20
MBq/kg Betalutin®) and 64% in Arm 1 (40 mg lilotomab followed by 15 MBq/kg
Betalutin®) in relapsed/refractory follicular lymphoma patients
. Median duration of response of 13.3 months for all patients (20.5 months for
those with a complete response)
. Well tolerated with predictable and manageable safety profileNordic Nanovector ASA (OSE: NANO) announces that an abstract reporting updated
results from its LYMRIT 37-01 Phase 1/2 clinical study of Betalutin® (177Lu
-satetraxetan-lilotomab) in patients with relapsed/refractory indolent non
-Hodgkin’s lymphoma (iNHL) has been published ahead of its presentation in a
poster at the 60th American Society of Hematology (ASH) Annual Meeting &
Exposition (1-4 December 2018 in San Diego, CA, USA).The published dataset (as of 22 June 2018) includes 74 evaluable patients; all
patients received Betalutin® as a single administration and have six or more
months of follow-up. The complete dataset will be presented at ASH.The conclusions from the updated study results are that Betalutin® is well
-tolerated and has promising anti-tumour activity in recurrent iNHL, especially
in follicular lymphoma (FL) patients. Key results are:±--------------------------±--------±------------±----------------------+
/Patients /Number of/Overall /Complete Responses (CR)/
/ /patients /Response Rate/ /
/ /(n) /(ORR) / /
±--------------------------±--------±------------±----------------------+
/All iNHL patients /74 /61 % /26 % /
±--------------------------±--------±------------±----------------------+
/FL patients /57 /65 % /24 % /
±--------------------------±--------±------------±----------------------+
/3L FL patients (?2 prior /37 /70 % /27 % /
/therapies) / / / /
±--------------------------±--------±------------±----------------------+
/FL patients in Arm 1 /25 /64 % /28 % /
/ (40 mg lilotomab followed/ / / /
/by 15 MBq/kg Betalutin®) / / / /
±--------------------------±--------±------------±----------------------+
/FL patients in Arm 4 /16 /69 % /19 % /
/ (100 mg/m2 lilotomab / / / /
/followed by 20 MBq/kg / / / /
/Betalutin®) / / / /
±--------------------------±--------±------------±----------------------+The median duration of response (mDoR), when treated with a single
administration of Betalutin®, was 13.3 months for all patients (20.5 months for
those with a CR) based on a median follow-up of 9.1 months (range 4.9-49.5
months). Twenty-six patients (35%) have remained free of disease progression for
more than 12 months.Betalutin® therapy was well tolerated with no unexpected safety findings and the
safety profile is both predictable and manageable.The data continue to highlight the encouraging clinical profile of single-agent
Betalutin® therapy in iNHL patients, particularly in those with FL, the primary
NHL population for which Betalutin® is being developed.Two recommended Phase 2 doses were identified from this study and are now being
compared in the pivotal, randomised Phase 2b PARADIGME trial in relapsed, anti
-CD20 refractory FL patients who have received two or more prior therapies.Arne Kolstad, lead investigator of LYMRIT 37-01 and senior consultant in medical
oncology and radiotherapy, Oslo University Hospital Radiumhospitalet, said:
“Patients with relapsed/refractory follicular lymphoma have a need for effective
treatment options that improve their quality of life, especially elderly
patients. The clinical profile that Betalutin® is consistently showing in this
patient population is very encouraging.”Lisa Rojkjaer, Chief Medical Officer of Nordic Nanovector, commented: “We are
very pleased with the clinical data. The results from Arm 4 further support the
decision to compare the 100 mg/m2 lilotomab + 20 MBq/kg Betalutin® dosing
regimen from Arm 4 with the 40 mg lilotomab + 15 MBq/kg regimen from Arm 1 in
the pivotal phase 2b PARADIGME trial. The emerging data on the durability of the
responses together with the safety profile of Betalutin® and the convenience of
a single administration underscore the potential of Betalutin® for the treatment
of patients with advanced-stage follicular lymphoma.”Poster details
Abstract 2879
Abstract title: LYMRIT 37-01: A phase I/II study of 177Lu-lilotomab
satetraxetan (Betalutin®) antibody-radionuclide-conjugate (ARC) for the
treatment of relapsed non-Hodgkin’s lymphoma (NHL) - Analysis with 6-month
follow-upAuthors: A. Kolstad, A et al.
Session Name: 623. Mantle Cell, Follicular, and Other Indolent B-Cell
Lymphoma-Clinical Studies: Poster IIDate: Sunday, 2 December 2018
Presentation Time: 6:00 PM - 8:00 PM Pacific time
Location: San Diego Convention Center, Hall GH
The abstract is available at http://www.hematology.org/Annual-Meeting/ and the
poster will be published on the Nordic Nanovector website to coincide with the
session.About ASH
The ASH annual meeting is the premier event for scientific exchange in the field
of haematology, attracting more than 20,000 attendees from all over the world.
Typically, more than 5,000 scientific abstracts are submitted each year, and
more than 3,000 abstracts are accepted for oral and poster presentations through
an extensive peer review process.About LYMRIT 37-01
LYMRIT 37-01 is a Phase 1/2 dose-escalation study to determine the safety,
pharmacokinetics and preliminary efficacy of a single dose of Betalutin® in
patients with relapsed iNHL, and to establish a recommended Phase 2 dose for the
global, randomised Phase 2b PARADIGME trial.LYMRIT 37-01 recruited 74 pts [57 follicular (FL), 7 mantle cell (MCL), 9
marginal zone (MZL), 1 small lymphocytic (SLL)] at 13 sites between December
2012 and February 2018. Median age was 68 years (range 38-87; 55% ? 65); the
median number of prior therapies was 3 (range 1-9); 48 pts (65%) received 2 or
more prior therapies.For further information, please contact:
IR enquiries
Malene Brondberg, VP Investor Relations and Corporate Communications
Cell: +44 7561 431 762
Email: [email protected]
International Media Enquiries
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44 207 638 9571
Email: [email protected]
About Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with
substantial unmet medical need, representing a growing market forecast to be
worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain
marketing rights and to actively participate in the commercialisation of
Betalutin® in core markets. Further information can be found at
www.nordicnanovector.comForward-looking statements
This press release contains certain forward-looking statements. These statements
are based on management’s current expectations and are subject to uncertainty
and changes in circumstances, since they relate to events and depend on
circumstances that will occur in the future and which, by their nature, will
have an impact on Nordic Nanovector’s business, financial condition and results
of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”,
“estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”,
“should”, “projects”, “targets”, “will”, “would” or, in each case, their
negative, or other variations or comparable terminology are used to identify
forward-looking statements. These forward-looking statements are not historic
facts. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied in the forward
-looking statements. Factors that could cause these differences include, but are
not limited to, risks associated with implementation of Nordic Nanovector’s
strategy, risks and uncertainties associated with the development and/or
approval of Nordic Nanovector’s product candidates, ongoing and future clinical
trials and expected trial results, the ability to commercialise Betalutin®,
technology changes and new products in Nordic Nanovector’s potential market and
industry, Nordic Nanovector’s freedom to operate (competitors patents) in
respect of the products it develops, the ability to develop new products and
enhance existing products, the impact of competition, changes in general economy
and industry conditions, and legislative, regulatory and political factors. No
assurance can be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any forward
-looking statements, whether as a result of new information, future events or
otherwise.This information is subject to a duty of disclosure pursuant to Section 5-1
Ekstern link: https://newsweb.oslobors.no/message/462626
Nyheten er levert av OBI.
http://www.netfonds.no/quotes/release.php?id=20181101.OBI.20181101S103
2 Likes
Denne hypemaskinen lever på likes og retweets.
3 Likes
Nordic Nanovector: Promising results from preclinical studies with a novel CD37-targeted alpha therapy for B-cell tumours to be presented at ASH
Oslo, Norway, 1 November 2018
Nordic Nanovector ASA (OSE: NANO) announces that an abstract reporting promising results from a research collaboration to develop a novel CD37-targeting alpha therapy for B-cell malignancies has been published. The complete results will be presented in a poster at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition (1-4 December 2018 in San Diego, CA, USA).
The research collaboration was established in June 2015 with Orano Med (formerly known as AREVA Med) to develop and investigate a next-generation targeted alpha therapy, comprising Nordic Nanovector’s chimeric anti-CD37 antibody (NNV003) and lead-212 (212Pb), for the treatment of B-cell malignancies.
The results published in the abstract relate to promising findings from preclinical studies investigating the dose-dependent efficacy and tolerability of 212Pb-NNV003 in human cell and mouse models of chronic lymphocytic leukaemia (CLL) and Burkitt’s lymphoma (a type of non-Hodgkin’s lymphoma, NHL).
In the studies, 212Pb-NNV003 was found to be well tolerated and led to a 90-100% survival rate in mouse models of CLL and NHL.
Jostein Dahle, Chief Scientific Officer of Nordic Nanovector, said: “There is a strong scientific rationale for combining our CD37-targeting approach with other cytotoxic payloads, including radionuclides and toxins. CD37 is an important target for B-cell malignancies as it is selectively expressed on the surface of B-cell malignancies. Alpha-particles have demonstrated good potential for targeted cancer therapies because their high energy is limited to a very short distance of just a few cell widths resulting in localised cytotoxicity while sparing surrounding healthy tissues. The development of 212Pb-conjugated CD37-targeted alpha therapy therefore offers the potential to treat leukaemias and lymphomas where there is no substantial tumour mass and tumour cells are near healthy tissues. We look forward to further results from this research programme.”
Abstract 4422
Abstract title: Targeted Alpha Therapy with 212Pb-NNV-003 for the Treatment of CD37 Positive B-Cell Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)
Authors: A. Saidi et al.
Session Name: 642. CLL: Therapy, excluding Transplantation: Poster III
Date: Monday, 3 December 2018
Presentation Time: 6:00 PM - 8:00 PM Pacific time
Location: San Diego Convention Center, Hall GH
The abstract is available at http://www.hematology.org/Annual-Meeting/ and the poster will be published on the Nordic Nanovector website to coincide with the session.
About ASH
The ASH annual meeting is the premier event for scientific exchange in the field of haematology, attracting more than 20,000 attendees from all over the world. Typically, more than 5,000 scientific abstracts are submitted each year, and more than 3,000 abstracts are accepted for oral and poster presentations through an extensive peer review process.
For further information, please contact:
IR enquiries
Malene Brondberg, VP Investor Relations and Corporate Communications
Cell: +44 7561 431 762
Email: [email protected]
International Media Enquiries
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44 207 638 9571
Email: [email protected]
About Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information can be found at www.nordicnanovector.com
About Orano Med
Orano Med (formerly AREVA Med) is a nuclear medicine biotech company developing innovative therapies in oncology. Orano Med has developed new processes for producing lead-212 (212Pb), a rare radioactive isotope used in Targeted Alpha Therapy (TAT), an innovative and promising approach of nuclear medicine allowing recognizing and destroying cancer cells while limiting the impact on nearby healthy cells. With its partners, Orano Med pursues the development of effective therapies to address patient needs. Orano Med is a subsidiary of Orano. More information about Orano Med: www.oranomed.com .
Forward-looking statements
This press release contains certain forward-looking statements. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector’s business, financial condition and results of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”, “estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”, “should”, “projects”, “targets”, “will”, “would” or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. These forward-looking statements are not historic facts. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in the forward-looking statements. Factors that could cause these differences include, but are not limited to, risks associated with implementation of Nordic Nanovector’s strategy, risks and uncertainties associated with the development and/or approval of Nordic Nanovector’s product candidates, ongoing and future clinical trials and expected trial results, the ability to commercialise Betalutin®, technology changes and new products in Nordic Nanovector’s potential market and industry, Nordic Nanovector’s freedom to operate (competitors patents) in respect of the products it develops, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions, and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This information is subject to a duty of disclosure pursuant to Section 5-12 of the Securities Trading Act.
Nyheten er levert av Cision.
http://www.netfonds.no/quotes/release.php?id=20181101.Cision.20181101:BIT:8957:0
3 Likes
In the studies, 212Pb-NNV003 was found to be well tolerated and led to a 90-100% survival rate in mouse models of CLL and NHL
16 Likes
Good!
Men skulle det ikke være en poster til som innbefattet DLBCL i kombinasjon med en kinase hemmer?
Positivt med preklinikse data fra dyr, kanskje kliniske forsøk ikke er så langt unna da?
Results
212Pb-NNV003 displays a favorable toxicity profile in tumor-free mice single intravenous dose injections up to 15 µCi showing 100 % survival 4 weeks post-injection. No acute hematological toxicity was observed and animals who received 5, 10 or 15 μCi doses of 212Pb-NNV003 presented only a slight initial reduction in their platelets (PLT) counts which was fully recovered by 20 days after injection.
A single intravenous dose of 10, 15 or 20 µCi of 212Pb-NNV003 lead to 70 %, 90 % and 100 % of mice injected with MEC-2 cells being tumor free 20 weeks post cell injection (Figure 1). Control animals that received saline, cold antibody or 212Pb-cetuximab presented a median survival of 4.9, 5.4 and 9.3 weeks, respectively.
A single intravenous dose of 2.5, 5 and 7.5 µCi 212Pb-NNV003 lead to over 80% tumor-free mice injected with Daudi cells 15 weeks post cell injection (Figure 2). Control animals that received saline, cold antibody or 212Pb-cetuximab presented a median survival of 7, 7.8 and 7.7 weeks, respectively.
Conclusion
The results of preclinical studies suggest that TAT using 212Pb-NNV003 is a safe and effective method for the treatment of CD37 positive CLL and NHL.
4 Likes